PersImmune is based in San Diego, CA. PersImmune is a clinical-stage immunotherapy company whose mission is to provide cancer patients with optimized immunotherapy personalized on the basis of their own unique tumor signature. PersImmune’s proprietary protocol, Personal Adoptive Cell Therapy for Neoantigens (PACTN) identifies the DNA alterations present in the cancer cells of each patient and generates enriched, tested, highly-specific T-cells that effectively kill the patient’s tumor cells. Personalized adoptive cellular therapy has the potential to transform the field of cancer treatment by providing safe, highly-tolerable, effective immunotherapy to cancer patients.

PersImmune was founded in 2010 by Dr. Antonella Vitiello, who was diagnosed and treated for a rare form of ovarian cancer in 2009.